Your browser is no longer supported. Please, upgrade your browser.
Dyne Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own15.00% Shs Outstand43.59M Perf Week-10.01%
Market Cap954.04M Forward P/E- EPS next Y-2.13 Insider Trans0.00% Shs Float18.73M Perf Month-5.24%
Income- PEG- EPS next Q-0.37 Inst Own87.20% Short Float8.57% Perf Quarter-9.69%
Sales- P/S- EPS this Y-208.90% Inst Trans50.21% Short Ratio3.48 Perf Half Y-
Book/sh8.42 P/B2.10 EPS next Y14.50% ROA- Target Price- Perf Year-
Cash/sh7.05 P/C2.51 EPS next 5Y- ROE- 52W Range15.60 - 32.31 Perf YTD-15.67%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-45.20% Beta-
Dividend %- Quick Ratio81.20 Sales past 5Y- Gross Margin- 52W Low13.53% ATR1.67
Employees36 Current Ratio81.20 Sales Q/Q- Oper. Margin- RSI (14)38.34 Volatility9.04% 6.98%
OptionableNo Debt/Eq0.03 EPS Q/Q- Profit Margin- Rel Volume0.99 Prev Close18.47
ShortableYes LT Debt/Eq0.03 Earnings- Payout- Avg Volume460.79K Price17.71
Recom1.60 SMA20-8.80% SMA50-17.62% SMA200-13.78% Volume442,548 Change-4.11%
Oct-12-20Initiated Stifel Buy $29
Oct-12-20Initiated Piper Sandler Overweight $34
Oct-12-20Initiated JP Morgan Overweight $27
Oct-12-20Initiated Jefferies Buy $47
Feb-08-21 07:30AM  
Jan-27-21 01:13AM  
Jan-20-21 08:05PM  
Jan-10-21 03:00PM  
Jan-05-21 07:30AM  
Dec-08-20 10:17AM  
Nov-09-20 07:30AM  
Nov-05-20 07:35AM  
Oct-09-20 03:41PM  
Sep-21-20 04:05PM  
Sep-16-20 07:00PM  
Dec-13-19 03:38PM  
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.